| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | KU-55933 | GDSC1000 | pan-cancer | AAC | -0.087 | 0.02 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.086 | 0.02 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.1 | 0.02 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.08 | 0.02 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | 0.079 | 0.02 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | -0.072 | 0.03 |
| mRNA | XL765 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.03 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | SCH-529074 | CTRPv2 | pan-cancer | AAC | -0.082 | 0.03 |